Cellosaurus K562/GM-CSF (CVCL_A8HT)
| Cell line name | K562/GM-CSF |
|---|---|
| Synonyms | K562 GM-CSF; K562GM-CSF; GM-K562 |
| Accession | CVCL_A8HT |
| Resource Identification Initiative | To cite this cell line use: K562/GM-CSF (RRID:CVCL_A8HT) |
| Comments | Population: Caucasian. Biotechnology: Used for the production of the Sorento Therapeutics STI-6991 SARS-CoV-2 (COVID-19) vaccine candidate. The cell line which is lethally irradiated is used to produce the recombinant SARS-CoV-2 spike protein rSARS-CoV-2 which is the active part of the vaccine formulation (PubMed=32289117). Characteristics: Does not express HLA class I or II antigens, potentially decreasing the magnitude of the alloresponses generated on repeated immunizations (PubMed=10466632). Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2434; CSF2. Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR). Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175. |
| Sequence variations |
|
| Disease | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C9110) Chronic myeloid leukemia (ORDO: Orphanet_521) |
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) |
| Hierarchy | Parent: CVCL_0004 (K-562) |
| Sex of cell | Female |
| Age at sampling | 53Y |
| Category | Cancer cell line |
| Publications | PubMed=10466632; DOI=10.1089/10430349950017347 PubMed=23170257; DOI=10.4161/onci.20954; PMCID=PMC3494623 PubMed=32289117; DOI=10.1016/j.medidd.2020.100026; PMCID=PMC7144842 |
| Cross-references | |
| Encyclopedic resources | Wikidata; Q107115522 |
| Entry history | |
| Entry creation | 20-May-2021 |
| Last entry update | 19-Dec-2024 |
| Version number | 9 |